This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
Avatar

Highlights of Recent Updates in Myeloma: Part 2 - R/R Treatment

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Andrzej Jakubowiak
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Andrzej Jakubowiak
203 views
July 31, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

2024 ASCO® Annual Meeting Insights Hub: Summaries & Highlights Videos

19:41
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 H&N Cancer Highlights: Key Insights From Clinical Tri…

Feat. K. Kerrigan
24:36
2024 ASCO® Annual Meeting Insights Hub

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

Feat. S. Aithal
15:07
2024 ASCO® Annual Meeting Insights Hub

Highlights of Recent Updates in CML: Impact on Practice

Feat. E. Atallah
View All

Related Content

AUTOPLAY
Moffitt Cancer Center

2024 Cell Coast Conference

Fri, Oct 25, 2024
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
24:35
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …

Feat. H. Hashmi
07:11
GRACE

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

Feat. A. Goodman, A. Jeong, S. Rajeeve
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
35:27
Dana-Farber Cancer Institute

Advances in Multiple Myeloma 2024: From Bench to Bedside

Feat. K. Anderson
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
13:47
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…

Feat. B. Derman
20:23
SOHO Brazil 2024

When to Consider Bispecific and CAR-T Therapy in MM

Feat. N. S. Raje
26:46
Samer Al Hadidi

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

22:33
Integrity CE

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Feat. S. Usmani, J. Hillengass
05:35
Saurabh Chhabra

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
03:42
Moffitt Cancer Center

Multiple Myeloma: What You Need to Know About New FDA Approvals of C…

Feat. D. Hansen
35:37
University of Colorado Division of Hematology

2024 Updates on Multiple Myeloma Treatment

Feat. D. Sherbenou
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani